Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 10/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.42 |
| ▸ | CFD | P00746 | 2/20 | 0.40 |
| ▸ | ELOC | Q15369 | 1/20 | 0.39 |
| ▸ | ELOB | Q15370 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26648469 | 1.00 | VHL (0.44) | VHLPOLBDPP4DPP8DPP9 | |
| SCHEMBL26648479 | 1.00 | VHL (0.44) | VHLPOLBDPP4DPP8DPP9 | |
| SCHEMBL30772007 | 0.88 | VHL (0.44) | VHLDPP4DPP8DPP9CFD | |
| SCHEMBL26648321 | 0.88 | VHL (0.44) | VHLDPP4DPP8DPP9ELOC | |
| SCHEMBL26648278 | 0.88 | VHL (0.42) | VHLDPP4DPP8DPP9CFD | |
| SCHEMBL26648287 | 0.88 | VHL (0.42) | VHLDPP4DPP8DPP9CFD | |
| SCHEMBL26648315 | 0.88 | VHL (0.44) | VHLDPP4DPP8DPP9ELOC | |
| SCHEMBL26648323 | 0.88 | VHL (0.44) | VHLDPP4DPP8DPP9ELOC | |
| SCHEMBL26648273 | 0.88 | VHL (0.42) | VHLDPP4DPP8DPP9CFD | |
| SCHEMBL30772026 | 0.87 | VHL (0.49) | VHLPOLBDPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | VHL 501/4885POLB 1482/4885DPP4 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.